GeoVax Highlights Mpox Threat After North Carolina Wastewater Detection
Wastewater samples in North Carolina reveal the first state detection of Clade I Mpox, a more virulent strain with higher transmissibility. GeoVax responds by emphasizing the need for expanded vaccine preparedness and domestic manufacturing capabilities.
The discovery of Clade I Mpox viral particles in North Carolina wastewater signals a potential emerging public health risk, according to biotechnology company GeoVax. State health officials confirmed the first detection of this more dangerous viral strain, which is associated with higher transmission rates and increased mortality compared to previously known Mpox variants.
Clade I Mpox represents a significant concern for public health experts. To date, four confirmed cases have been reported across the United States in California, Georgia, New Hampshire, and New York. The detection in North Carolina's wastewater suggests potential silent transmission of the virus before clinical cases become apparent.
In response, GeoVax is accelerating development of GEO-MVA, a domestically produced vaccine candidate targeting Mpox and smallpox. The company aims to reduce reliance on a single overseas vaccine supplier and enhance national biosecurity. GeoVax has completed cGMP manufacturing of the vaccine and plans to initiate clinical trials in the second half of 2025.
The wastewater detection highlights the critical importance of robust viral surveillance systems. However, proposed federal funding cuts could compromise these early warning networks, potentially leaving communities vulnerable to emerging viral threats. Experts emphasize the need for continued investment in surveillance infrastructure and domestic vaccine manufacturing capabilities.
As the Mpox landscape evolves, GeoVax's vaccine development represents a strategic approach to pandemic preparedness, offering a potential domestic solution to emerging viral challenges and reducing dependence on international vaccine sources.